Introduction {#ss1}
============

The landmark prospective randomized clinical trials (RCT) from the UK Prospective Diabetes Study (UKPDS) showed that improving glycemic control, as assessed by hemoglobin A1c (HbA~1c~) levels, reduces the risks of complications in type 2 diabetes[^1--3^](#b1 b2 b3){ref-type="ref"}. To achieve adequate glycemic control, many type 2 diabetics after failing on oral hypoglycemic agents (OHA) will eventually require insulin therapy as deterioration of β‐cell function and loss of β‐cell mass progresses over time[^4,5^](#b4 b5){ref-type="ref"}. Recent American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) consensus statements recommend the early initiation of basal insulin therapy as a result of their simplicity and feasibility, combined with OHA in patients not achieving acceptable glucose control[^6^](#b6){ref-type="ref"}. The two available long‐acting insulin analogs, including insulin glargine and insulin detemir, have been designed to provide more consistent, relative flat and protracted basal insulin levels than intermediate‐acting insulin[^7^](#b7){ref-type="ref"}.

However, there is a general uncertainty as to whether basal insulin based on regimens will help as many patients achieve glycemic control as biphasic insulin and rapid‐acting insulin preparations based on regimens[^8,9^](#b8 b9){ref-type="ref"}. Initial 1‐year data from the Treating‐to‐Target in Type 2 diabetes (4‐T) study showed that less than one‐third of patients who were assigned to receive the long‐acting insulin analog to oral therapy reached a HbA~1c~ level below the recommended 7% target, which was lower than that of the biphasic and rapid‐acting insulin analog[^10^](#b10){ref-type="ref"}. Previous meta‐analyses studies found that HbA~1c~ reduction might be obtained in type 2 diabetes when insulin is initiated with biphasic or prandial insulin regimens rather than basal regimens[^8,9^](#b8 b9){ref-type="ref"}. Nevertheless, after those publications, further results after 3‐year follow up from the 4‐T study have been published, in which they reported patients who added to a long‐acting insulin analog or rapid‐acting insulin analog‐based regimens achieved better glycemic control than a biphasic insulin analog‐based regimen[^11^](#b11){ref-type="ref"}.

Therefore, the optimal insulin regimen to start with when OHA fails to control glucose in type 2 diabetes is far more uncertain[^8,9,12^](#b8 b9 b12){ref-type="ref"}. In the present study, we present up‐to‐date data from a systemic review and meta‐analyses of RCT, which aimed to assess the comparative effectiveness and safety of regimens based on long‐acting insulin analogs compared with other injectable preparations in insulin‐naïve patients with type 2 diabetes failing on oral agents.

Materials and Methods {#ss2}
=====================

Inclusion and Exclusion Criteria {#ss3}
--------------------------------

We included RCT if they reported data for comparing long‐acting insulin analog‐based regimens vs one of the following injectable agents‐based regimens -- rapid‐acting insulin analogs, or biphasic insulin analogs, or NPH insulin, or glucagon‐like peptide‐1 (GLP‐1) analogs -- with a duration of 12 weeks or longer, and recruited insulin‐naive adults (\>18 years) with type 2 diabetes inadequately controlled with oral agents. Pooled analyses on human biphasic insulin or intermediate‐acting insulin analog were not possible, because only one study for each comparison was reported. We limited the research to English‐language studies; non‐English‐language studies were excluded, because the quality of these studies is difficult to evaluate. If we identified more than one publication of an original study, we assessed those articles together to maximize data collection. Citations were excluded if: (i) the intervention time was \<12 weeks; (ii) the use of OHA was unbalanced between study arms; (iii) they related to type 1 diabetes; or (iv) there was a history of insulin treatment.

Outcome Measures {#ss4}
----------------

In the present study, we present results for intermediate clinical outcomes of HbA~1c~; fasting glucose; postprandial glucose; weight gain; daily insulin dose by bodyweight; the incidence of total, nocturnal and severe hypoglycemia; and the incidence of any adverse events, treatment‐related adverse events and withdrawal as a result of adverse events.

Search Strategy {#ss5}
---------------

We searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (1980 to March 2010) to identify relevant RCT trials using terms of type 2 diabetes, long‐acting insulin, detemir or levemir, glargine or lantus.

Data Extraction and Study Quality Assessment {#ss6}
--------------------------------------------

Two investigators independently reviewed relevant publications and abstracted the data, and any disagreements were resolved by consensus and discussion with a third reviewer. Methodological quality was assessed using criteria set out by Jadad[^13^](#b13){ref-type="ref"}, with an additional point given if the analysis was by intention‐to‐treat[^8^](#b8){ref-type="ref"}.

Data Synthesis and Statistical Analysis {#ss7}
---------------------------------------

Data were combined by using a random‐effects model (Review Manager Version 4.2.10; The Cochrane Collaboration, Copenhagen, Denmark). For the evaluation of outcomes, we combined parallel and crossover trials, because no crossover studies reported carryover effects. Data from intention‐to‐treat studies were recorded after intention‐to‐treat principles.

For the evaluation of outcomes of HbA~1c~, fasting, postprandial glucose and weight gain, the changes between baseline and end‐point were used for the comparisons between groups. Standard deviation (SD) was recorded from studies or calculated from the baseline, and final SD using a correlation of 0.5 or from 95% confidence intervals (CI) and *P*‐values for the difference in means (Cochrane Collaboration, 2004). Definitions of hypoglycemia varied among studies ([Table 1](#t1){ref-type="table-wrap"}). The most consistently reported measure of hypoglycemia was the percentage of participants experiencing an episode of a specific type of hypoglycemia (symptomatic, asymptomatic, nocturnal and severe). Therefore, we chose to combine this measure by calculating the incidence of participants experiencing an episode of a specific type for each intervention as an overall indicator of hypoglycemia.

######  Characteristics of included studies

  Author, Year, Reference                                                      Groups                                                                  Study length (weeks)   Patients (*n*)   Men (%)   Mean age (years)   Mean BMI (kg/m^2^)   Diabetes duration (years)   Start HbA~1c~ (%)   Start FPG (mmol/L)   Hypoglycemia (\<mmol/L)   Previous treatment                               Quality score
  ---------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------- ---------------- --------- ------------------ -------------------- --------------------------- ------------------- -------------------- ------------------------- ------------------------------------------------ ---------------
  Long‐acting insulin analogs vs rapid‐acting insulin analogs                                                                                                                                                                                                                                                                                                                                    
   Holman 2009[^11^](#b11){ref-type="ref"}                                     Detemir vs aspart, SU was replaced by second insulin if necessary       148                    473              62.4      61.8               29.7                 9                           8.5                 9.6                  3.1                       MET+SU                                           4
   Bretzel 2008[^15^](#b15){ref-type="ref"} (intention‐to‐treat)               Glargine vs lispro, both plus previous OHA                              44                     377              57        59.7               29.25                8.85                        8.7                 10.1                 3.3                       MET/SU/TZD/α‐Glucosidase inhibitors              4
   Kazda 2006[^16^](#b16){ref-type="ref"}                                      Glargine vs lispro                                                      24                     105              52.5      59.8               30.4                 5.4                         8.2                 9.7                  3                         MET/SU/TZD/ α‐Glucosidase inhibitors/Glinides    3
  Long‐acting insulin analogs vs biphasic insulin analogs                                                                                                                                                                                                                                                                                                                                        
   Holman 2009[^11^](#b11){ref-type="ref"}                                     Detemir vs BIAsp70/30, SU was replaced by second insulin if necessary   148                    469              64.5      61.8               30.0                 9                           8.5                 9.6                  3.1                       MET+ SU                                          4
   Kazda 2006[^16^](#b16){ref-type="ref"}                                      Glargine vs lisproMix50/50                                              24                     107              51.4      58.9               30.1                 5.7                         8.1                 9.5                  3                         MET/SU/TZD/ α‐Glucosidase inhibitors/Glinides    3
   Strojek 2009[^17^](#b17){ref-type="ref"} (intention‐to‐treat)\*             Glargine vs BIAsp70/30, plus MET + SU                                   26                     469              43.9      56                 29.1                 9.3                         8.5                 \_                   3.1                       MET/SU                                           3
   Buse 2009[^18^](#b18){ref-type="ref"} (intention‐to‐treat)                  Glargine vs lisproMix 75/25, plus previous OHA                          24                     2091             52.8      57                 32                   9.5                         9.05                10.8                 3.9                       MET/SU/TZD                                       3
   Raskin 2005[^19^](#b19){ref-type="ref"}    (intention‐to‐treat)             Glargine vs BIAspart 70/30, plus MET                                    28                     233              54.5      52.4               31.5                 9.2                         9.77                13.8                 3.1                       MET/other agents                                 3
   Malone 2004[^20^](#b20){ref-type="ref"} (crossover) (intention‐to‐treat)    Glargine vs lisproMix75/25, plus MET                                    16                     105              62.9      55                 30.4                 8.95                        8.7                 8.5                  3.5                       MET/SU/Glinides  /α‐Glucosidase inhibitors/TZD   4
   NCT00377858[^21^](#b21){ref-type="ref"} (intention‐to‐treat)                Glargine plus lispro vs lisproMix                                       36                     479              47.6      59                 29.3                 11.3                        9.47                \_                   3.9                       Two or thee OHA                                  3
  Long‐acting insulin analogs vs intermediate‐acting human NPH insulin                                                                                                                                                                                                                                                                                                                           
   De Mattia 2009[^22^](#b22){ref-type="ref"} (cross‐over)                     Glargine vs NPH, plus previous OHAs                                     24                     20               70        59.4               29.5                 \_                          9.3                 11.3                 \_                        MET+SU                                           2
   Pan 2007[^23^](#b23){ref-type="ref"}\*                                      Glargine vs NPH, plus SU                                                24                     443              42.5      56.1               24.95                10.15                       9.035               12.5                 2.8                       SU + other OHA                                   2
   Eliaschewitz 2006[^24^](#b24){ref-type="ref"}                               Glargine vs NPH, plus SU                                                24                     481              40.5      56.6               27.25                10.55                       9.15                11.1                 2.8                       SU/MET/α‐Glucosidase inhibitor                   2
   Yki‐Jarvinen 2006[^25^](#b25){ref-type="ref"} (intention‐to‐treat)          Glargine vs NPH, plus MET                                               36                     110              63.5      56.5               31.65                9                           9.55                13                   4                         MET/SU                                           4
   Philips‐Tsimikas 2006 [^26^](#b26){ref-type="ref"} (intention‐to‐treat)     Detemir vs NPH, plus previous OHA                                       20                     333              56.8      58.5               30                   10.3                        9.04                11.1                 3.1                       MET/SU/TZD/α‐Glucosidase inhibitor               4
    Hermansen 2006[^27^](#b27){ref-type="ref"} (intention‐to‐treat)\*          Detemir vs NPH, plus previous OHA                                       24                     475              53.1      60.9               29.0                 9.7                         8.56                11                   4                         MET/SU/α‐Glucosidase inhibitor                   4
   Riddle 2003[^28^](#b28){ref-type="ref"} (intention‐to‐treat)                Glargine vs NPH, plus previous OHA                                      24                     756              55.5      55.5               32.35                8.7                         8.59                10.9                 4                         SU/MET/TZD                                       4
   Fritsche 2003[^29^](#b29){ref-type="ref"} (intention‐to‐treat)              Glargine vs NPH, plus SU                                                28                     459              53.7      61                 28.7                 8.8                         9.1                 12.1                 4.2                       SU/MET/α‐Glucosidase inhibitor                   4
   Yki‐Jarvinen 2000[^30^](#b30){ref-type="ref"} (intention‐to‐treat)          Glargine vs NPH, plus previous OHA                                      52                     422              54        59                 28.9                 10                          9                   \_                   2.8                       MET/SU/α‐Glucosidase inhibitor                   4
  Long‐acting insulin analogs vs GLP‐1 analogs                                                                                                                                                                                                                                                                                                                                                   
   Davies 2009[^31^](#b31){ref-type="ref"} (intention‐to‐treat)                Glargine vs exenatide, plus previous OHA                                26                     234              68.4      56.5               34.1                 8.7                         8.57                10.5                 3.4                       MET/SU/TZD                                       3
   Bunck 2009[^32^](#b32){ref-type="ref"} (intention‐to‐treat)                 Glargine vs exentide, plus MET                                          52                     69               65.3      58.4               30.5                 4.85                        7.5                 9.2                  3.3                       MET                                              3
   Russell‐Jones[^33^](#b33){ref-type="ref"} (intention‐to‐treat)              Glargine vs liraglutide, plus MET + SU                                  26                     462              58.5      57.6               30.4                 9.5                         8.3                 9.1                  3.1                       MET/SU                                           4
   Barnett 2007[^34^](#b34){ref-type="ref"} (crossover) (intention‐to‐treat)   Glargine vs exenatide, plus previous OHA                                16                     114              47.1      54.9               31.1                 7.4                         8.95                12.1                 3.3                       MET/SU                                           4
   Heine 2005[^35^](#b35){ref-type="ref"} (intention‐to‐treat)\*               Glargine vs exenatide, plus previous OHA                                26                     549              55.8      58.9               31.4                 9.55                        8.25                10.3                 3.4                       MET + SU                                         4

BMI, body mass index; GLP‐1, glucagon‐like peptide‐1; MET, metformin; NPH, neutral protamine Hagedorn; NPL, neutral protamine Lispro; OHA, oral hypoglycemic agent; SU, sulfonylurea; TZD, thiazolidinedione.

\*Standard deviation of difference between baseline and end of study was calculated according to the approach indicated in Cochrane Collaboration, 2004 ([http://www.cochrane‐net.org](http://www.cochrane-net.org)).

Continuous outcomes were calculated by weighted mean differences (WMD) with 95% CI. Dichotomous outcomes were summarized as odds ratio (OR) with 95% CI. We determined heterogeneity by using an *I*^2^ statistic[^14^](#b14){ref-type="ref"}, and we carried out subgroup analysis for: (i) baseline HbA~1c~ (\<9%, ≥9%; as the failure criteria used in different studies); (ii) quality score (\<3, ≥3); (iii) variation in study length; (iv) oral agents given as added‐on therapy (yes or not) or the nature of the oral agents used in combination with insulin; and (v) long‐acting insulin analogs (glargine, detemir). We carried out sensitivity analyses to determine whether inclusion of studies deemed to be of low methodological quality affected the results. Funnel plots were used to assess the potential for publication bias and small sample size.

Results {#ss8}
=======

Study Characteristics {#ss9}
---------------------

In total, data from 9548 participants in 22 RCT studies were included ([Figure 1](#f1){ref-type="fig"}). A total of 19 were parallel groups and three were crossovers. A total of 17 studies were analyzed according to intention‐to‐treat principles. A total of 15 studies described randomization methods[^11,15,17,18,20,25--30,32--35^](#b11 b15 b17 b18 b20 b25 b26 b27 b28 b29 b30 b32 b33 b34 b35){ref-type="ref"}. No study was double‐blinded. The median quality score of included studies was 3. The study participants had a mean age of 57.7 years, mean body mass index of 30.1 kg/m^2^, mean duration of diabetes of 9.0 years, and 55.6% were male. The median duration of follow up was 34 weeks, and average study size was 434 participants. Participants had a median HbA~1c~ level of 8.8%, and median fasting plasma glucose of 10.9 mmol/L. A total of 20 studies included the use of oral glucose‐lowering medications in conjunction with insulin ([Table 1](#t1){ref-type="table-wrap"}).

![ Study flow diagram (*n* = number of trial reports). RCT, randomized clinical trials.](jdi-3-283-g1){#f1}

Long‐acting Insulin Analogs vs Rapid‐acting Insulin Analogs {#ss10}
-----------------------------------------------------------

### HbA~1c~ {#ss11}

Pooling studies showed that long‐acting insulin analogs were not statistically significant to rapid‐insulin analogs in decreasing HbA~1c~ (WMD 0.32%, 95% CI −0.02 to 0.65), but this varied between studies (*I*^2^ = 75.3%; [Figure 2a](#f2){ref-type="fig"})[^11,15,16^](#b11 b15 b16){ref-type="ref"}. Heterogeneity was substantially reduced when a study with shorter diabetes duration and lower baseline HbA~1c~ was removed (WMD 0.14%, 95% CI −0.02 to 0.29; *I*^2^ = 0%)[^16^](#b16){ref-type="ref"}. The SD for the change in one study were imputed from baseline and final SD[^15^](#b15){ref-type="ref"}.

![ (a) Long‐acting insulin analogs vs rapid‐acting insulin analogs. (b) Long‐acting insulin analogs vs biphasic insulin analogs. (c) Long‐acting insulin analogs vs intermediate‐acting human neutral protamine Hagedorn (NPH) insulin. (d) Long‐acting insulin analogs vs glucagon‐like peptide‐1 (GLP‐1) analogs. WMD, weighted mean differences.](jdi-3-283-g2){#f2}

### Fasting Glucose and Postprandial Glucose {#ss12}

Pooling studies showed that long‐acting insulin analogs were not statistically significant to rapid‐acting insulin analogs in decreasing fasting glucose (WMD −1.36 mmol/L, 95% CI −3.21 to 0.49), but with high heterogeneity (*I*^2^ = 97.2%), which was not explained by baseline HbA~1c~ levels or combination therapy of OHA or treatment targets[^11,15,16^](#b11 b15 b16){ref-type="ref"}. However, long‐acting insulin analogs were less effective than rapid‐acting insulin analogs in decreasing morning postprandial glucose (WMD 0.78 mmol/L, 95% CI 0.38--1.19) with no heterogeneous (*I*^2^ = 5.3%; [Table 2](#t2){ref-type="table-wrap"})[^11,15,16^](#b11 b15 b16){ref-type="ref"}.

######  Pooled results for comparisons

  Outcome title                                                  No. studies   No. participants   Statistical method   Effect size            *P*‐value   
  -------------------------------------------------------------- ------------- ------------------ -------------------- ---------------------- ----------- ------
  Change in fasting glucose (mmol/L)                                                                                                                      
   Long‐acting insulin analogs vs rapid‐acting insulin analogs   3             470 vs 481         WMD (95% CI)         −1.36 (−3.21, 0.49)    0.15        97.2
   Long‐acting insulin analogs vs biphasic insulin analogs       4             1311 vs 1289       WMD (95% CI)         −0.57 (−1.29, 0.14)    0.11        87.2
   Long‐acting insulin analogs vs human NPH insulin              6             1206 vs 1246       WMD (95% CI)         −0.20 (−0.38, −0.02)   0.03        0
   Long‐acting insulin analogs vs GLP‐1 analogs                  4             468 vs 484         WMD (95% CI)         −1.35 (−1.64, −1.06)   \<0.0001    0
  Change in postprandial glucose (mmol/L)                                                                                                                 
   Long‐acting insulin analogs vs rapid‐acting insulin analogs   3             465 vs 478         WMD (95% CI)         0.78 (0.38, 1.19)      0.0001      5.3
   Long‐acting insulin analogs vs biphasic insulin analogs       3             398 vs 390         WMD (95% CI)         −0.52 (−1.25, 0.21)    0.17        67.3
  Change in weight (kg)                                                                                                                                   
   Long‐acting insulin analogs vs rapid‐acting insulin analogs   3             465 vs 478         WMD (95% CI)         −1.57 (−3.01. −0.13)   0.03        73.3
   Long‐acting insulin analogs vs biphasic insulin analogs       4             1311 vs 1289       WMD (95% CI)         −1.25 (−1.64, −0.87)   \<0.0001    5.3
   Long‐acting insulin analogs vs human NPH insulin              6             1208 vs 1199       WMD (95% CI)         −0.32 (−1.10, 0.45)    0.41        6.3
   Long‐acting insulin analogs vs GLP‐1 analogs                  5             688 vs 696         WMD (95% CI)         4.12 (3.25, 4.99)      \<0.0001    74.8
  Daily insulin doses by bodyweight (U/kg)                                                                                                                
   Long‐acting insulin analogs vs rapid‐acting insulin analogs   2             279 vs 287         WMD (95%CI)          −0.01 (−0.16, 0.14)    0.91        59.7
   Long‐acting insulin analogs vs biphasic insulin analogs       6             1646 vs 1617       WMD (95% CI)         −0.07 (−0.14, 0.00)    0.04        87.2
   Long‐acting insulin analogs vs human NPH insulin              5             896 vs 925         WMD (95% CI)         0.03 (0.01, 0.06)      0.01        99.3
  Incidence of total hypoglycemia (%)                                                                                                                     
   Long‐acting insulin analogs vs rapid‐acting insulin analogs   3             465 vs 478         OR (95% CI)          0.23 (0.05, 1.13)      0.07        91.2
   Long‐acting insulin analogs vs biphasic insulin analogs       6             1789 vs 1759       OR (95% CI)          0.72 (0.56, 0.94)      0.01        61.2
   Long‐acting insulin analogs vs human NPH insulin              6             998 vs 999         OR (95% CI)          0.57 (0.45, 0.72)      \<0.00001   30.3
  Incidence of severe hypoglycemia (%)                                                                                                                    
   Long‐acting insulin analogs vs biphasic insulin analogs       3             1265 vs 1231       OR (95% CI)          0.62 (0.31, 1.21)      0.16        0
   Long‐acting insulin analogs vs human NPH insulin              5             1185 vs 1235       OR (95% CI)          0.78 (0.45, 1.35)      0.37        20.8
   Long‐acting insulin analogs vs GLP‐1 analog                   3             423 vs 429         OR (95% CI)          1.55 (0.37, 6.57)      0.55        55.8
  Incidence of nocturnal hypoglycemia (%)                                                                                                                 
   Long‐acting insulin analogs vs biphasic insulin analogs       3             1256 vs 1237       OR (95% CI)          0.99 (0.84, 1.16)      0.89        0
   Long‐acting insulin analogs vs human NPH insulin              4             851 vs 878         OR (95% CI)          0.46 (0.37, 0.58)      \<0.0001    0
  Incidence of any adverse events (%)                                                                                                                     
   Long‐acting insulin analogs vs rapid‐acting insulin analogs   3             465 vs 478         OR (95% CI)          1.51 (0.65, 3.50)      0.33        65.6
   Long‐acting insulin analogs vs biphasic insulin analogs       3             1372 vs 1348       OR (95% CI)          0.78 (0.60, 1.02)      0.07        0
   Long‐acting insulin analogs vs human NPH insulin              4             648 vs 654         OR (95% CI)          0.86 (0.67, 1.11)      0.25        19.6
   Long‐acting insulin analogs vs GLP‐1 analog                   3             430 vs 436         OR (95% CI)          0.33 (0.13, 0.85)      0.02        84
  Incidence of treatment related adverse events (%)                                                                                                       
   Long‐acting insulin analogs vs human NPH insulin              3             646 vs 667         OR (95% CI)          1.23 (0.82, 1.86)      0.32        6.3
   Long‐acting insulin analogs vs GLP‐1 analog                   3             430 vs 436         OR (95% CI)          0.04 (0.03, 0.06)      \<0.0001    0
  Withdrawal due to adverse events (%)                                                                                                                    
   Long‐acting insulin analogs vs human NPH insulin              3             672 vs 701         OR (95% CI)          0.68 (0.27, 1.67)      0.39        0
   Long‐acting insulin analogs vs GLP‐1 analog                   4             460 vs 466         OR (95% CI)          0.19 (0.05, 0.66)      0.009       37.9

GLP‐1, glucagon‐like peptide‐1; NPH, neutral protamine Hagedorn; WMD, weighted mean differences.

### Weight Gain {#ss13}

Pooling citations showed that, compared with rapid‐acting insulin analogs, long‐acting insulin analogs were significantly associated with less weight gain (WMD −1.57 kg, 95% CI −3.01 to −0.13), but with heterogeneity (*I*^2^=73.3%; [Table 2](#t2){ref-type="table-wrap"})[^11,15,16^](#b11 b15 b16){ref-type="ref"}. However, subgroup analysis after removing a study with longer study length and the use of detemir as the comparator did not show statistical differences between the two groups with no heterogeneity (WMD −0.77 kg, 95% CI −1.55 to 0.01; *I*^2^ = 20.3%)[^11^](#b11){ref-type="ref"}.

### Daily Insulin Dose by Bodyweight {#ss14}

Pooling studies showed no significant differences in daily insulin dosages between rapid‐acting insulin analogs and long‐acting insulin analogs (WMD −0.01 IU/kg per day, 95% CI −0.16 to 0.14), but with heterogeneity (*I*^2^ = 59.7%; [Table 2](#t2){ref-type="table-wrap"})[^11,16^](#b11 b16){ref-type="ref"}.

### Hypoglycemia {#ss15}

Pooling studies showed no significant difference in incidence of total hypoglycemia between long‐acting and rapid‐acting insulin analogs (OR 0.23, 95% CI 0.05--1.13), but with heterogeneity (*I*^2^ = 91.2%), which was not explained by baseline HbA~1c~ levels or combination therapy of OHA or two long‐acting insulin analogs ([Table 2](#t2){ref-type="table-wrap"})[^11,15,16^](#b11 b15 b16){ref-type="ref"}. Pooled analysis on severe hypoglycemia or nocturnal hypoglycemia was not possible as a result of insufficient data. Two citations[^11,15^](#b11 b15){ref-type="ref"} reported no significant differences in rates of severe hypoglycemia and one citation[^15^](#b15){ref-type="ref"} observed no significant differences in rates of nocturnal hypoglycemia between two treatment arms.

### Adverse Events {#ss16}

Pooling studies showed no significant difference in any adverse events between long‐acting and rapid‐acting insulin analogs (OR 1.51, 95% CI 0.65--3.5), but with heterogeneity (*I*^2^ = 65.6%), which was not explained by baseline HbA~1c~ levels or combination therapy of OHA, or one form of two long‐acting insulin analogs ([Table 2](#t2){ref-type="table-wrap"})[^11,15,16^](#b11 b15 b16){ref-type="ref"}. Pooled analysis on treatment‐related adverse events or withdrawal a result of adverse events was not possible because of insufficient data.

Long‐acting Insulin Analogs vs Biphasic Insulin Analogs {#ss17}
-------------------------------------------------------

### HbA~1c~ {#ss18}

Pooling studies showed that long‐acting insulin analogs were less effective than biphasic insulin analogs in decreasing HbA~1c~ (WMD 0.19%, 95% CI 0.04--0.34; [Figure 2b](#f2){ref-type="fig"}), but this effect varied between studies (*I*^2^ = 58.7%)[^11,16--21^](#b11 b16 b17 b18 b19 b20 b21){ref-type="ref"}. Heterogeneity was substantially reduced when a study with shorter diabetes duration and lower baseline HbA~1c~ was removed (WMD 0.11%, 95% CI 0.02--0.19; *I*^2^ = 0%)[^16^](#b16){ref-type="ref"}. The SD for change in three studies were calculated, in which two studies were imputed from 95% CI and *P*‐values for the difference in means[^17,21^](#b17 b21){ref-type="ref"}, and the other study was imputed from the baseline and final SD[^19^](#b19){ref-type="ref"}.

### Fasting Glucose and Postprandial Glucose {#ss19}

Pooling studies showed that long‐acting insulin analogs were not statistically significant to biphasic insulin analogs in decreasing fasting glucose (WMD −0.57 mmol/L, 95% CI −1.29 to 0.14)[^11,16,18,19^](#b11 b16 b18 b19){ref-type="ref"} and morning postprandial glucose (WMD −0.52 mmol/L, 95% CI −1.25 to 0.21)[^11,16,19^](#b11 b16 b19){ref-type="ref"}, but with high heterogeneity (fasting glucose *I*^2^ = 87.2%; postprandial glucose *I*^2^ = 67.3%; [Table 2](#t2){ref-type="table-wrap"}). Heterogeneity in fasting glucose or postprandial glucose was not explained by baseline HbA~1c~ levels or combination therapy of OHA or the treatment target. The SD for change in two studies were calculated from the baseline and final SD[^18,19^](#b18 b19){ref-type="ref"}.

### Weight Gain {#ss20}

Pooling citations showed that, compared with biphasic insulin analogs, long‐acting insulin analogs were significantly associated with less weight gain (WMD −1.25kg, 95% CI −1.64 to −0.87), the effect was not heterogeneous (*I*^2^ = 5.3%; [Table 2](#t2){ref-type="table-wrap"})[^11,16,18,19^](#b11 b16 b18 b19){ref-type="ref"}.

### Daily Insulin Dose by Bodyweight {#ss21}

Pooling studies showed daily insulin dosages by bodyweight in long‐acting insulin analogs group were lower than those in biphasic insulin analogs group (WMD −0.07 IU/kg per day, 95% CI −0.14 to 0.00), but with heterogeneity (*I*^2^ = 87.2%; [Table 2](#t2){ref-type="table-wrap"})[^11,17--21^](#b11 b17 b18 b19 b20 b21){ref-type="ref"}.

### Hypoglycemia {#ss22}

Pooling studies showed that long‐acting insulin analogs were associated with a lower incidence of total hypoglycemia compared with biphasic insulin analogs (OR 0.72, 95% CI 0.56--0.94), but this was highly varied (*I*^2^ = 61.2%)[^11,16--19,21^](#b11 b16 b17 b18 b19 b21){ref-type="ref"}. Heterogeneity was substantially reduced when a study with higher baseline HbA~1c~ (9.77%) was removed (OR 0.82, 95% CI 0.71--0.94; *I*^2^ = 0%)[^19^](#b19){ref-type="ref"}. Pooling studies reported a non‐significant difference in incidence of nocturnal hypoglycemia (OR 0.99, 95% CI 0.84--1.16)[^18,20,21^](#b18 b20 b21){ref-type="ref"} and severe hypoglycemia (OR 0.62, 95% CI 0.31--1.21)[^17--19^](#b17 b18 b19){ref-type="ref"} between two treatment arms, the effects were not heterogeneous for both comparisons (*I*^2^ = 0%; [Table 2](#t2){ref-type="table-wrap"}).

### Adverse Events {#ss23}

Pooling three studies showed no significant difference in incidence of any adverse events between long‐acting and biphasic insulin analogs (OR 0.78, 95% CI 0.60--1.02) ([Table 2](#t2){ref-type="table-wrap"})[^11,17,18^](#b11 b17 b18){ref-type="ref"}. Pooled analysis on treatment‐related adverse events or withdrawal as a result of adverse events was not possible because of insufficient data.

Long‐acting Insulin Analogs vs Intermediate‐acting Human NPH Insulin {#ss24}
--------------------------------------------------------------------

### HbA~1c~ {#ss25}

Pooling studies showed that change of HbA~1c~ from baseline to study end‐point was not statistically significant between two treatment arms (WMD −0.02%, 95% CI −0.11 to 0.07; [Figure 2c](#f2){ref-type="fig"}), the effect was not heterogeneous between studies (*I*^2^ = 36.3%)[^22--30^](#b22 b23 b24 b25 b26 b27 b28 b29 b30){ref-type="ref"}. The SD of change in six studies were imputed from baseline and final SD[^23,25,27--30^](#b23 b25 b27 b28 b29 b30){ref-type="ref"}.

### Fasting Glucose and Postprandial Glucose {#ss26}

Pooling citations showed that long‐acting insulin analogs were superior in decreasing fasting glucose compared with NPH insulin (WMD −0.20 mmol/L, 95% CI −0.38 to −0.02), the effect was not heterogeneous (*I*^2^ = 0%; [Table 2](#t2){ref-type="table-wrap"})[^23--26,28,29^](#b23 b24 b25 b26 b28 b29){ref-type="ref"}. Pooled analysis on postprandial glucose was not possible as a result of lack of data.

### Weight Gain {#ss27}

Pooling citations showed that long‐acting insulin analogs and NPH insulin have similar effects on weight gain (WMD −0.32 kg, 95% CI −1.10 to −0.45), but this varied highly (*I*^2^ = 86.3%; [Table 2](#t2){ref-type="table-wrap"})[^25--30^](#b25 b26 b27 b28 b29 b30){ref-type="ref"}. Heterogeneity was substantially reduced when two studies with detemir were removed (WMD 0.16 kg, 95% CI −0.25 to 0.56; *I*^2^ = 0%)[^26,27^](#b26 b27){ref-type="ref"}. Furthermore, pooling these two citations with detemir showed that detemir has less weight gain than NPH (WMD −1.26 kg, 95% CI −1.70 to −0.83), but with high heterogeneity (*I*^2^ = 60%)[^26,27^](#b26 b27){ref-type="ref"}. The SD for change in two studies were calculated from 95% CI and *P*‐values for the difference in means[^26,27^](#b26 b27){ref-type="ref"}.

### Daily Insulin Dose by Bodyweight {#ss28}

Pooling studies showed daily insulin dosages by bodyweight in the long‐acting insulin analogs group were higher than those in the NPH insulin group (WMD 0.03 IU/kg per day, 95% CI 0.01--0.06), but with heterogeneity (*I*^2^ = 99.3%; [Table 2](#t2){ref-type="table-wrap"})[^22,24,26,28,30^](#b22 b24 b26 b28 b30){ref-type="ref"}.

### Hypoglycemia {#ss29}

Pooling citations showed that long‐acting insulin analogs were associated with a lower incidence of total hypoglycemia (OR 0.57, 95% CI 0.45--0.72)[^24--27,29^](#b24 b25 b26 b27 b29){ref-type="ref"} and nocturnal hypoglycemia[^24,26,27,29^](#b24 b26 b27 b29){ref-type="ref"} (OR 0.46, 95% CI 0.37--0.58) compared with NPH insulin; both the effect estimates were not heterogeneous (*I*^2^ = 30.3% for total hypoglycemia and *I*^2^ = 0% for nocturnal hypoglycemia). Pooling citations reported a non‐significant difference in incidence of severe hypoglycemia between two arms (OR 0.78, 95% CI 0.45--1.35), the effect was not heterogeneous (*I*^2^ = 20.8%; [Table 2](#t2){ref-type="table-wrap"})[^24,26--29^](#b24 b26 b27 b28 b29){ref-type="ref"}.

### Adverse Events {#ss30}

Pooling citations showed a non‐significant difference in any adverse events (OR 0.86, 95% CI 0.67--1.11)[^23--26^](#b23 b24 b25 b26){ref-type="ref"}, treatment‐related adverse events (OR 1.23, 95% CI 0.82--1.86)[^23,24,27^](#b23 b24 b27){ref-type="ref"} and withdrawal as a result of adverse events (OR 0.68, 95% CI 0.27--1.67)[^25,27,29^](#b25 b27 b29){ref-type="ref"} between long‐acting insulin analogs and NPH insulin. The effects were not heterogeneous for all these outcomes (any adverse events *I*^2^ = 19.6%; treatment‐related adverse events *I*^2^ = 6.3%; withdrawal as a result of adverse events, *I*^2^ = 0%; [Table 2](#t2){ref-type="table-wrap"}).

Long‐acting Insulin Analog vs GLP‐1 Analogs {#ss31}
-------------------------------------------

### HbA~1c~ {#ss32}

Pooling citations showed a non‐significant difference in change of HbA~1c~ from baseline to study end‐point between two treatment arms (WMD −0.05%, 95% CI −0.05 to 0.15), the effect was not heterogeneous (*I*^2^ = 0%; [Figure 2d](#f2){ref-type="fig"})[^31--35^](#b31 b32 b33 b34 b35){ref-type="ref"}. The SD of change in one study were imputed from 95% CI for differences in means[^35^](#b35){ref-type="ref"}.

### Fasting Glucose and Postprandial Glucose {#ss33}

Pooling four citations showed that long‐acting insulin analog was superior in decreasing fasting glucose (WMD −1.35 mmol/L, 95% CI −1.64 to −1.06) than GLP‐1 analogs, the effect was not heterogeneous (*I*^2^ = 0%; [Table 2](#t2){ref-type="table-wrap"})[^31,32,34,35^](#b31 b32 b34 b35){ref-type="ref"}. Pooled analysis on postprandial glucose was not possible as a result of lack of data.

### Weight Change {#ss34}

Pooling five citations showed that, compared with GLP‐1 analogs, long‐acting insulin analog was associated with greater weight gain (WMD 4.12 kg, 95% CI 3.25--4.99), but with high heterogeneity (*I*^2^ = 74.8%; [Table 2](#t2){ref-type="table-wrap"})[^31--35^](#b31 b32 b33 b34 b35){ref-type="ref"}. Heterogeneity was reduced when a study with higher starting body mass index was removed (WMD 3.81 kg, 95% CI 3.39--4.23; *I*^2^ = 35.5%)[^31^](#b31){ref-type="ref"}. The SD for change in one study were calculated from 95% CI and *P*‐values for the difference in means[^35^](#b35){ref-type="ref"}.

### Hypoglycemia {#ss35}

Pooled analysis on total or nocturnal hypoglycemia was not possible as a result of different units between studies. Four studies reported no differences in the episode or incidence or event of total hypoglycemia between two treatment arms[^31,33--35^](#b31 b33 b34 b35){ref-type="ref"}. One study reported that hypoglycemia was more frequent in the glargine group (24.2 vs 8.3%, *P*‐value was not shown)[^33^](#b33){ref-type="ref"}. In addition, three citations reported GLP‐1 analogs were significantly associated with a lower risk of nocturnal hypoglycemia than long‐acting insulin analogs[^32,33,35^](#b32 b33 b35){ref-type="ref"}. Pooling citations reported no difference in severe hypoglycemia between two treatment arms (OR 1.55, 95% CI 0.37--6.57), but with high heterogeneity (*I*^2^ = 55.8%; [Table 2](#t2){ref-type="table-wrap"})[^31,34,35^](#b31 b34 b35){ref-type="ref"}. Heterogeneity was reduced (OR 0.89, 95CI 0.36--2.23; *I*^2^ = 0%) when a study with higher duration and baseline HbA~1c~ was removed[^34^](#b34){ref-type="ref"}.

### Adverse Events {#ss36}

Pooling citations showed that, compared with GLP‐1 analogs, long‐acting insulin analog was associated with less incidence of any adverse events (OR 0.33, 95% CI 0.13--0.85)[^31,34,35^](#b31 b34 b35){ref-type="ref"}, treatment‐related adverse events (OR 0.04, 95% CI 0.03--0.06)[^31,34,35^](#b31 b34 b35){ref-type="ref"}, and withdrawal as a result of adverse events (OR 0.19, 95% CI 0.05--0.66)[^31,32,34,35^](#b31 b32 b34 b35){ref-type="ref"}. The effect estimates were heterogeneous for any adverse events (*I*^2^ = 84%), but not heterogeneous for treatment‐related adverse events and withdrawal as a result of adverse events (treatment‐related adverse events *I*^2^ = 0%; withdrawal as a result of adverse events *I*^2^ = 37.9%; [Table 2](#t2){ref-type="table-wrap"}).

Discussion {#ss37}
==========

We found that all the included preparations helped to keep reducing HbA~1c~ levels by an average of 1.1--1.6% with 29--72 weeks follow up. Long‐acting insulin analogs‐based regimens were not statistically significant to rapid‐acting insulin analogs or NPH insulin or GLP‐1 analogs‐based regimens in terms of decreasing HbA~1c~. Where there were statistical differences between long‐acting insulin analogs and biphasic insulin analogs‐based regimens in decreasing HbA~1c~, the differences (0.19%) were sufficiently small to have minimal if any clinical significance.

We observed that the clinical benefits of long‐acting insulin analogs were associated with less weight gain over biphasic insulin analogs. The superiority in less weight gain of long‐acting insulin analogs over rapid‐acting insulin analogs was inconsistent as a result of heterogeneity. Pooling analysis on studies with detemir or glargine noted that detemir, but not glargine, was associated with less weight gain over NPH insulin, consistent with other reviews[^36,37^](#b36 b37){ref-type="ref"}. Long‐acting insulin analogs were associated with greater weight gain in comparison with GLP‐1 analogs.

As well, we found clinical advantages for long‐acting insulin analogs over biphasic insulin analogs in the incidence of total hypoglycemia. Long‐acting insulin analogs were associated with a lower incidence of total hypoglycemia and nocturnal hypoglycemia over NPH insulin.

In addition, long‐acting insulin analogs were superior to GLP‐1 analogs in fewer risks of any adverse events, treatment related adverse events and withdrawal as a result of adverse events. It should be stated that many of the treatment‐related adverse events with GLP‐1 analogs are related to gastrointestinal side‐effects, notably nausea, vomiting and diarrhea. The pooled analysis on micro‐ and macrovascular complications was not possible, because no study evaluated these long‐term outcomes.

These results are important, because the aim of early intensive treatment is glycemic control without induction of hypoglycemia or weight gain, and in the long‐term, reduction in micro‐ and macrovascular complications. UKPDS showed that a lower 0.9% of HbA~1c~ value was associated with a reduced 25% (*P* = 0.0099) risk of microvascular complications and a reduced 16% (*P* = 0.052) risk of myocardial infarction compared with conventional therapy[^38^](#b38){ref-type="ref"}. This suggests that reduced HbA~1c~ levels by an average of 1.1--1.6% in our analyses might well equate to significantly reduced risks of complications. The difference between long‐acting insulin analogs and biphasic insulin analogs appeared to be slight (0.19%), and the difference for subgroup analysis after removing heterogeneity was even less (0.11%). There are insufficient data to determine whether marginal reduction in HbA~1c~ is of benefit in reducing diabetes‐related complications. It has, however, been reviewed by us and others[^8^](#b8){ref-type="ref"} that biphasic insulin decreased HbA~1c~ level at the expense of an increased risk of total hypoglycemia and more weight gain. It seems likely that long‐acting insulin initiation by means of one injection might facilitate patients' acceptance of insulin initiation[^39^](#b39){ref-type="ref"}.

Inconsistent with our findings to some extent, previous reviews observed that a greater reduction of 0.45% in HbA~1c~ was seen for biphasic and prandial insulin‐based regimens compared with basal insulin based on regimens in type 2 diabetics failing on OHA[^8^](#b8){ref-type="ref"}. Given the weight of the 4‐T study in the meta‐analysis, these findings could be partly explained by the included 3‐year results, in which the superiority of the prandial and biphasic insulin relative to basal insulin at 1‐year disappeared or decreased. The difference emphasizes the need to carry out long‐term, high‐quality studies specifically designed to determine the clinical outcomes, which are particularly important in the setting of chronic disease, such as type 2 diabetes.

The present study had limitations. The ability to understand the heterogeneity for all comparisons remains limited as a result of a small number of studies and variations in quality of studies. To address this limitation, a random‐effects model was used for analysis regardless of the presence or absence of statistical heterogeneity. The small number of studies also limited our ability to fully address the potential publication bias. Furthermore, we included studies that included both crossover and parallel designs. These might be the potential sources of heterogeneity of findings. However, it did reflect the state of clinical research in this area; and consistent with our findings, previous reviews also had such methodological limitations[^8,9^](#b8 b9){ref-type="ref"}.

In conclusion, for insulin‐naïve patients with type 2 diabetes failing on oral agents, initiating long‐acting insulin analogs seems likely to provide glycemic control similar to rapid‐acting insulin analogs or NPH insulin or GLP‐1 analogs and is marginally inferior in glycemic control compared with biphasic insulin analogs with fewer side‐effects. High‐quality studies are needed to evaluate the long‐term effects of insulin preparations on clinical outcomes.
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